Radiopeptide imaging and therapy in Europe

Journal of Nuclear Medicine

Volumn 52, Issue SUPPL. 2, 2011, Pages

  Ambrosini, Valentina ^a   Fani, Melpomeni ^b   Fanti, Stefano ^a   Forrer, Flavio ^c   Maecke, Helmut R ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Europe; Imaging; Radiopeptide; Therapy

Indexed keywords

3,4 DIHYDROXYPHENYLALANINE F 18; 6 HYDRAZINONICOTINAMIDE OCTREOTIDE[3 TYROSINE 8 THREONINE] TC 99M; 6 HYDRAZINONICOTINAMIDE OCTREOTIDE[3 TYROSINE] TC 99M; ARGINYLGLYCYLASPARTIC ACID; BOMBESIN; CHOLECYSTOKININ; CHOLECYSTOKININ B RECEPTOR; DEPREOTIDE TC 99M; DOTA GA 68; DOTA LU 177; DOTA Y 90; DOTANOC GA 68; DOTATATE GA 68; DOTATATE Y 90; DOTATOC GA 68; DOTATOC Y 90; G PROTEIN COUPLED RECEPTOR; GASTRIN RECEPTOR; GASTRIN RELEASING PEPTIDE; GLUCAGON LIKE PEPTIDE 1; LANREOTIDE DOTA Y 90; LANREOTIDE Y 90; OCTREOTIDE[3 TYROSINE] I 125; PENTETATE INDIUM IN 111; PENTETREOTIDE IN 111; RADIOPEPTIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; SUBSTANCE P; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; BLOOD TOXICITY; DRUG CLEARANCE; DRUG DOSE ESCALATION; EUROPE; HUMAN; ISOTOPE LABELING; LUNG NODULE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN TARGETING; RADIOACTIVITY; RADIOTHERAPY; REVIEW; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR LOCALIZATION;

ANIMALS; DIAGNOSTIC IMAGING; EUROPE; HUMANS; ISOTOPE LABELING; NEOPLASMS; PEPTIDES; RADIOTHERAPY;

EID: 83755225132     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.085753     Document Type: Review

References (120)

1. Sundin A, Garske U, Orlefors H. Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007;21:69-85. (Pubitemid 46421900)
2. Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54(suppl 4):iv1-iv16. (Pubitemid 40695259)
3. Reubi JC, Landolt AM. High density of somatostatin receptors in pituitary tumors from acromegalic patients. J Clin Endocrinol Metab. 1984;59:1148-1151. (Pubitemid 15223351)
4. Krenning EP, Bakker WH, Breeman WA, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989;1:242-244.
5. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-731. (Pubitemid 23284773)
6. Asnacios A, Courbon F, Rochaix P, et al. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol. 2008;26:963-970. (Pubitemid 351398091)
7. Goldsmith SJ. Update on nuclear medicine imaging of neuroendocrine tumors. Future Oncol. 2009;5:75-84.
8. Maina T, Stolz B, Albert R, Bruns C, Koch P, Macke H. Synthesis, radiochemistry and biological evaluation of a new somatostatin analogue (SDZ 219-387) labelled with technetium-99m. Eur J Nucl Med. 1994;21:437-444. (Pubitemid 24135917)
9. Béhé M, Maecke HR. New somatostatin analogues labelled with technetium-99m [abstract]. Eur J Nucl Med. 1995;22(suppl):791P.
10. 111In-labelled octreotide derivatives. Eur J Nucl Med. 2000;27:1318-1325.
11. 111In-DTPA-D-Phe1-octreotide. Eur J Nucl Med. 2000;27:628-637.
12. 99mTc-Demotate 1: first data in tumour patients - results of a pilot/phase I study. Eur J Nucl Med Mol Imaging. 2003;30:1211-1219.
13. 111In- pentetreotide scintigraphy. J Nucl Med. 2002;43:889-895.
14. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Eur J Nucl Med Mol Imaging. 2006;33:1123-1133.
15. 99mTc-EDDA/HYNIC]octreotate in intra-operative detection of neuroendocrine tumours of the gastrointestinal tract. Eur J Nucl Med Mol Imaging. 2007;34:1545-1555.
16. 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs. J Nucl Med. 2008;49:1060-1065.
17. Antunes P, Ginj M, Zhang H, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34:982-993. (Pubitemid 46919547)
18. Hofmann M, Maecke H, Borner R, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;28:1751-1757. (Pubitemid 33815052)
19. 111In]-DTPAOC SPECT: first results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003;5:42-48.
20. 68Ga-DOTA-Tyr3- octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-518.
21. 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med. 2009;50:1214-1221.
22. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273-282. (Pubitemid 30167697)
23. 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010;51:875-882.
24. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2008;35:72-79.
25. 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:1431-1438.
26. 68Ga-DOTA-NOC PET. Biomed Pharmacother. 2008;62:667-671.
27. 68Ga-DOTA- NOC receptor PET/CT. Eur J Nucl Med Mol Imaging. 2010;37:67-77.
28. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010;51:669-673.
29. 68Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med. 2010;51:353-359.
30. 68Ga-DOTA-TATE PET/CT in the detection of GEP NETs [abstract]. Eur J Nucl Med Mol Imaging 2009;36(suppl 2):S201.
31. 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2009;36:765-770.
32. 68Ga-DOTATOC PET/CT datasets demonstrates different degrees of differentiation. Eur J Nucl Med Mol Imaging. 2007;34:812.
33. 18F-FDG. Cancer. 2008;112:2447-2455.
34. 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging. 2006;33:1115-1122.
35. Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA. 2006;103:16436-16441. (Pubitemid 44715214)
36. 68Ga-somatostatin antagonists: the chelate makes the difference. J Nucl Med. 2011;52:1110-1118.
37. Fjälling M, Andersson P, Forssell-Aronsson E, et al. Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome. J Nucl Med. 1996;37:1519-1521. (Pubitemid 26321635)
38. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med. 2000;41:1704-1713.
39. Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med. 2002;32:110-122. (Pubitemid 34311077)
40. De Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002;32:133-140. (Pubitemid 34311079)
41. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006;36:228-247. (Pubitemid 43817847)
42. Schottelius M, Wester HJ. Molecular imaging targeting peptide receptors. Methods. 2009;48:161-177.
43. Otte A, Jermann E, Behe M, et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med. 1997;24:792-795. (Pubitemid 27356860)
44. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 1998;351:417-418. (Pubitemid 28064170)
45. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001;12:941-945.
46. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med. 2002;43:610-616. (Pubitemid 34507110)
47. 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res. 2006;26:703-707.
48. 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging. 2003;30:207-216.
49. 90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1038-1046.
50. 90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006;36:147-156.
51. Smith MC, Liu J, Chen T, et al. OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy. Digestion. 2000;62(suppl 1):69-72. (Pubitemid 30665942)
52. 90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29:2416-2423.
53. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med. 2002;32:148-155. (Pubitemid 34311081)
54. Baum RP, Prasad V, Hommann M, Horsch D. Receptor PET/CT imaging of neuroendocrine tumors. Recent Results Cancer Res. 2008;170:225-242.
55. Baum RP, Söldner J, Schmücking M, Niesen A. Peptidrezeptorvermittelte radiotherapie (PRRT) neuroendokriner tumoren. Klinischen indikationen und erfahrung mit 90yttrium-markierten somatostatinanaloga. Der Onkologie. 2004;10:1098-1110. (Pubitemid 39555978)
56. Cwikla JB, Sankowski A, Seklecka N, et al. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann Oncol. 2010;21:787-794.
57. 177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30:417-422.
58. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124-2130.
59. 90Y-DOTATOC. J Nucl Med. 2005;46:1310-1316.
60. 177Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery. 2006;140:968-976.
61. 177Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Q J Nucl Med Mol Imaging. 2010;54:84-91.
62. 177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging. 2011;38:1788-1797.
63. Körner M, Stockli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 2007;48:736-743. (Pubitemid 47604973)
64. Wiesli P, Brandle M, Schmid C, et al. Selective arterial calcium stimulation and hepatic venous sampling in the evaluation of hyperinsulinemic hypoglycemia: potential and limitations. J Vasc Interv Radiol. 2004;15:1251-1256. (Pubitemid 39487855)
65. Placzkowski KA, Vella A, Thompson GB, et al. Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987-2007. J Clin Endocrinol Metab. 2009;94:1069-1073.
66. Wild D, Christ E, Caplin ME, et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med. 2011;52:1073-1078.
67. Wild D, Macke H, Christ E, Gloor B, Reubi JC. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med. 2008;359:766-768.
68. Christ E, Wild D, Forrer F, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab. 2009;94:4398-4405.
69. Kroog GS, Jensen RT, Battey JF. Mammalian bombesin receptors. Med Res Rev. 1995;15:389-417.
70. Carroll RE, Ostrovskiy D, Lee S, Danilkovich A, Benya RV. Characterization of gastrin-releasing peptide and its receptor aberrantly expressed by human colon cancer cell lines. Mol Pharmacol. 2000;58:601-607.
71. Gugger M, Reubi JC. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol. 1999;155:2067-2076.
72. Reubi JC, Korner M, Waser B, Mazzucchelli L, Guillou L. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging. 2004;31:803-810. (Pubitemid 38758349)
73. Sun B, Halmos G, Schally AV, Wang X, Martinez M. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate. 2000;42:295-303. (Pubitemid 30104573)
74. Sun B, Schally AV, Halmos G. The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers. Regul Pept. 2000;90:77-84. (Pubitemid 30331013)
75. Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med. 2005;46(suppl 1):67S-75S. (Pubitemid 47619021)
76. Van de Wiele C, Dumont F, Vanden Broecke R, et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med. 2000;27:1694-1699.
77. 99mTc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. J Nucl Med. 2001;42:1722-1727.
78. Van de Wiele C, Phonteyne P, Pauwels P, et al. Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry. J Nucl Med. 2008;49:260-264. (Pubitemid 351225665)
79. 64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties. Bioconjug Chem. 2007;18:1110-1117.
80. Rogers BE, Bigott HM, McCarthy DW, et al. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjug Chem. 2003;14:756-763. (Pubitemid 36875435)
81. 64Cu-labeled polyethylene glycol-bombesin conjugate. Cancer Biother Radiopharm. 2004;19:25-34.
82. Boswell CA, Sun X, Niu W, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem. 2004;47:1465-1474. (Pubitemid 38327472)
83. Garrison JC, Rold TL, Sieckman GL, et al. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med. 2007;48:1327-1337. (Pubitemid 47242799)
84. Mansi R, Wang X, Forrer F, et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging. 2011;38:97-107.
85. 68Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. Bioconjug Chem. 2009;20:1016-1025.
86. 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer. J Nucl Med. 2011;52:470-477.
87. Zhang H, Chen J, Waldherr C, et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res. 2004;64:6707-6715. (Pubitemid 39302601)
88. 18F-FDG. J Nucl Med. 2007;48:1245-1250.
89. Dimitrakopoulou-Strauss A, Seiz M, Tuettenberg J, et al. Pharmacokinetic studies of Ga-labeled bombesin (Ga-BZH) and F-18 FDG PET in patients with recurrent gliomas and comparison to grading: preliminary results. Clin Nucl Med. 2011;36:101-108.
90. 64Cu-CB-TE2A-AR-06 in mice and men [abstract]. J Nucl Med. 2011;52(suppl 1):7P.
91. 177Lu-AMBA bombesin analogue in hormone refractory prostate cancer patients: a phase I escalation study with single-cycle administrations [abstract]. Eur J Nucl Med Mol Imaging. 2007;34(suppl 2):S221.
92. Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res. 1997;57:1377-1386. (Pubitemid 27152565)
93. Behr TM, Jenner N, Behe M, et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med. 1999;40:1029-1044. (Pubitemid 29269226)
94. Gotthardt M, Behe MP, Grass J, et al. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocr Relat Cancer. 2006;13:1203-1211. (Pubitemid 46212574)
95. Gotthardt M, Behe MP, Beuter D, et al. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2006;33:1273-1279. (Pubitemid 44630781)
96. Behr TM, Behe MP. Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med. 2002;32:97-109. (Pubitemid 34311076)
97. Kolenc-Peitl P, Mansi R, Tamma M, et al. Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor. J Med Chem. 2011;54:2602-2609.
98. Ocak M, Helbok A, Rangger C, et al. Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607. Eur J Nucl Med Mol Imaging. 2011;38:1426-1435.
99. 111In-labelled gastrin/CCK2 receptor-targeting peptides. Eur J Nucl Med Mol Imaging. 2011;38:1410-1416.
100. 18F]galacto-RGD. PLoS Med. 2005;2:e70.
101. 18F] galacto-RGD identifies the level of integrin alphavbeta3 expression in man. Clin Cancer Res. 2006;12:3942-3949.
102. 18F-galacto-RGD in cancer patients. J Nucl Med. 2005;46:1333-1341.
103. 18F-FDG. J Nucl Med. 2008;49:22-29.
104. 18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:6610-6616.
105. 18F- galacto-RGD PET. J Nucl Med. 2008;49:255-259.
106. 18F] galacto-RGD positron emission tomography. Neuro Oncol. 2009;11:861-870.
107. Bach-Gansmo T, Danielsson R, Saracco A, et al. Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. J Nucl Med. 2006;47:1434-1439. (Pubitemid 47544928)
108. 18F-AH111585 in breast cancer patients. J Nucl Med. 2008;49:879-886.
109. 18F]AH- 111585 PET imaging to detect tumours and angiogenesis. ClinicalTrials.gov Web site. Available at: http://clinicaltrials.gov/ct2/show/NCT00565721?term=A+proof- of-concept+study+to+assess+the+ability+AH- 111585+PET+imaging+to+detect+tumours+and+angiogenesis&rank=1. Accessed November 9, 2011.
110. Cho HJ, Lee JD, Park JY, et al. First in human evaluation of a newly developed PET tracer, 18FRGD-K5 in patients with breast cancer: comparison with 18FFDG uptake pattern and microvessel density [abstract]. J Nucl Med. 50(suppl 2):403P.
111. 18F]RGD-K5 positron emission tomography (PET) as a tool to monitor response to an antiangiogenic drug (K5-101). ClinicalTrials.gov Web site. Available at: http://clinicaltrials.gov/ct2/show/ NCT00988936?term=Efficacy+study+of+RGD- K5+positron+emission+ tomography+%28PET% 29+as+a+tool+ to+monitor+ response+ to+an+antiangiogenic+drug+%28K5-101%29&rank=1. Accessed November 9, 2011.
112. Haubner R, Beer AJ, Wang H, Chen X. Positron emission tomography tracers for imaging angiogenesis. Eur J Nucl Med Mol Imaging. 2010;37(suppl 1):S86-S103.
113. 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas. Clin Cancer Res. 1999;5:1025-1033.
114. 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med Mol Imaging. 2002;29:486-493.
115. Hennig IM, Laissue JA, Horisberger U, Reubi JC. Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer. 1995;61:786-792.
116. Kneifel S, Cordier D, Good S, et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p. Clin Cancer Res. 2006;12:3843-3850. (Pubitemid 44000266)
117. 90Y-labelled substance P radiotherapy for malignant gliomas. Eur J Nucl Med Mol Imaging. 2007;34:1388-1395.
118. Cordier D, Forrer F, Kneifel S, et al. Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P: results from a phase I study. J Neurooncol. 2010;100:129-136.
119. 213Bi-DOTA- [Thi8,Met(O2)11]-substance P: a pilot trial. Eur J Nucl Med Mol Imaging. 2010;37:1335-1344.
120. Mamelak AN, Rosenfeld S, Bucholz R, et al. Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol. 2006;24:3644-3650. (Pubitemid 46630539)